Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
Accession Number
DB10076
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated / Toxoid / Conjugate
Description

Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by Haemophilus influenzae type b. H. influenzae is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis. The vaccine contains the Haemophilus influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the H. influenzae type b strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid 1. The toxoid antigen is purified and toxin-inactivated.

Synonyms
  • Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ActHIBKit10 ug/0.5mLSanofi Pasteur Inc.1993-03-30Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
MenhibrixHaemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL)Injection, powder, lyophilized, for solutionIntramuscularGlaxoSmithKline Biologicals SA2013-09-032013-11-27Us
MenhibrixHaemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL)KitGlaxoSmithKline Biologicals SA2013-09-032017-09-17Us
PentacelHaemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5mL)KitSanofi Pasteur Limited2008-06-20Not applicableUs
Categories
UNII
FLV5I5W26R
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with 2-Methoxyethanol.
25-desacetylrifapentineThe therapeutic efficacy of Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with 25-desacetylrifapentine.
6-Deoxyerythronolide BThe therapeutic efficacy of Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Acetylsalicylic acid.
ActeosideThe therapeutic efficacy of Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Adalimumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Dailymed Label: ACTHIB- haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen [Link]
External Links
PubChem Substance
347910467

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionBacterial Infections; Virus Diseases1
2CompletedPreventionDiphtheria / Pertussis / Poliomyelitis / Tetanus / Viral Hepatitis B1
2CompletedPreventionHaemophilus Infections / Haemophilus Influenzae Type B / Meningococcal Infections / Neisseria Meningitidis1
2CompletedPreventionHaemophilus Influenza Type B1
2CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis2
2CompletedPreventionInfections, Rotavirus / Rotavirus Gastroenteritis1
2CompletedPreventionMeningitis / Meningococcal Infections1
2Unknown StatusPreventionInfectious Diseases1
3Active Not RecruitingPreventionDiphtheria / Meningitis, Bacterial / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionBacterial Infections / Virus Diseases2
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Whooping Cough1
3CompletedPreventionDiphtheria / Pertussis / Poliomyelitis1
3CompletedPreventionHaemophilus Influenzae Infections / Haemophilus Influenzae Type B / Neisseria Meningitidis / Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine1
3CompletedPreventionHaemophilus Influenzae Type B1
3CompletedPreventionHaemophilus Influenzae Type B / Haemophilus Influenzae Type B Infection / Meningococcal Infections / Neisseria Meningitidis2
3CompletedPreventionHepatitis A / Hepatitis A Vaccine1
3CompletedPreventionImmunization; Infection1
3CompletedPreventionImmunizations1
3CompletedPreventionInvasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y / Meningococcal Infections1
3CompletedPreventionMeningococcal Meningitis1
3RecruitingPreventionInfections, Pneumococcal1
3RecruitingPreventionInfections, Pneumococcal / Vaccines, Pneumococcal1
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus1
4CompletedTreatmentPain NOS1
Not AvailableActive Not RecruitingNot AvailableDiphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus1
Not AvailableCompletedNot AvailableDiphtheria / Haemophilus Influenzae / Pertussis / Tetanus1
Not AvailableCompletedNot AvailablePertussis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit10 ug/0.5mL
Injection, powder, lyophilized, for solutionIntramuscular
Kit
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on November 30, 2015 14:23 / Updated on June 04, 2019 07:13